P2RY12 and stroke disorder: We also reviewed the limitations of current adenosine-related therapies (e.g., P2Y12-targeted drugs) and existing knowledge gaps.<h4>Results</h4>Post-stroke, dying and stressed neuronal cells increase ATP release, which is converted to adenosine by extracellular enzymes, forming an adenosine-rich immunosuppressive microenvironment.